高尿酸血症和高心血管风险患者诊断与治疗的专家共识：2023年更新版 - Suppr | 超能文献

Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update.

作者信息

Borghi Claudio, Domienik-Karłowicz Justyna, Tykarski Andrzej, Filipiak Krzysztof J, Jaguszewski Milosz J, Narkiewicz Krzysztof, Barylski Marcin, Mamcarz Artur, Wolf Jacek, Mancia Giuseppe

机构信息

Department of Medical and Surgical Sciences, University of Bologna, Italy.

Department of Internal Medicine and Cardiology with the Center for Diagnosis and Treatment of Venous Thromboembolism, Medical University of Warsaw, Poland.

出版信息

Cardiol J. 2024;31(1):1-14. doi: 10.5603/cj.98254. Epub 2023 Dec 29.

DOI:10.5603/cj.98254

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10919576/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d3b/10919576/cfc421e41daf/cardj-31-1-1f1.jpg

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update.

Cardiol J. 2024;31(1):1-14. doi: 10.5603/cj.98254. Epub 2023 Dec 29.

2

Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk.

Cardiol J. 2018;25(5):545-563. doi: 10.5603/CJ.2018.0116.

3

[Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice].

Ter Arkh. 2019 Dec 15;91(12):75-83. doi: 10.26442/00403660.2019.12.000173.

4

[Hyperuricemia and uro-nephrological disorders].

Presse Med. 2011 Sep;40(9 Pt 1):865-8. doi: 10.1016/j.lpm.2011.05.006. Epub 2011 Jun 17.

5

Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Cardiol J. 2021;28(1):1-14. doi: 10.5603/CJ.a2021.0001. Epub 2021 Jan 13.

6

[Hyperuricemia and atherosclerosis].

Nihon Rinsho. 2003 Jan;61 Suppl 1:259-65.

7

Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population.

Sci Rep. 2017 Jul 14;7(1):5456. doi: 10.1038/s41598-017-05751-w.

8

Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.

Int J Mol Sci. 2021 Aug 26;22(17):9221. doi: 10.3390/ijms22179221.

9

Hyperuricemia and Cardiovascular Disease in Patients with Hypertension.

Conn Med. 2016 Feb;80(2):85-90.

10

Hyperuricemia, the heart, and the kidneys - to treat or not to treat?

Ren Fail. 2020 Nov;42(1):978-986. doi: 10.1080/0886022X.2020.1822185.

引用本文的文献

1

Sex-specific associations between blood urea nitrogen and risk of hyperuricemia in U.S. adults: the NHANES 1999-2020.

Front Endocrinol (Lausanne). 2025 Jun 5;16:1560738. doi: 10.3389/fendo.2025.1560738. eCollection 2025.

2

Muscle quality index and hyperuricemia: adipose tissue as a mediator.

Front Endocrinol (Lausanne). 2025 May 27;16:1562837. doi: 10.3389/fendo.2025.1562837. eCollection 2025.

3

Blood Biomarkers as a Non-Invasive Method for the Assessment of the State of the Fontan Circulation.

J Clin Med. 2025 Jan 14;14(2):496. doi: 10.3390/jcm14020496.

4

Development and validation of an interpretable machine learning model for predicting left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients.

PLoS One. 2025 Jan 16;20(1):e0313562. doi: 10.1371/journal.pone.0313562. eCollection 2025.

5

Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study.

Nutrients. 2024 Jul 19;16(14):2324. doi: 10.3390/nu16142324.

本文引用的文献

1

Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials.

J Clin Rheumatol. 2024 Mar 1;30(2):e46-e53. doi: 10.1097/RHU.0000000000002045. Epub 2023 Dec 20.

2

Hyperuricemia as a Risk Factor in Hypertension among Patients with Very High Cardiovascular Risk.

Healthcare (Basel). 2023 Sep 3;11(17):2460. doi: 10.3390/healthcare11172460.

3

Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration-A Novel Mechanism of Action.

J Cardiovasc Dev Dis. 2023 Jun 22;10(7):268. doi: 10.3390/jcdd10070268.

4

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).

J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26.

5

Serum uric acid and left ventricular mass index independently predict cardiovascular mortality: The uric acid right for heart health (URRAH) project.

Eur J Intern Med. 2023 Aug;114:58-65. doi: 10.1016/j.ejim.2023.04.010. Epub 2023 Apr 23.

6

Serum Uric Acid Predicts All-Cause and Cardiovascular Mortality Independently of Hypertriglyceridemia in Cardiometabolic Patients without Established CV Disease: A Sub-Analysis of the URic acid Right for heArt Health (URRAH) Study.

Metabolites. 2023 Feb 7;13(2):244. doi: 10.3390/metabo13020244.

7

Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan.

Front Cardiovasc Med. 2023 Jan 10;9:1062894. doi: 10.3389/fcvm.2022.1062894. eCollection 2022.

8

Serum uric acid significantly improves the accuracy of cardiovascular risk score models.

Eur J Prev Cardiol. 2023 May 9;30(7):524-532. doi: 10.1093/eurjpc/zwac275.

9

The Prevalence of Hyperuricemia and Its Correlates among Adults in China: Results from CNHS 2015-2017.

Nutrients. 2022 Oct 2;14(19):4095. doi: 10.3390/nu14194095.

10

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.

Lancet. 2022 Oct 8;400(10359):1195-1205. doi: 10.1016/S0140-6736(22)01657-9.